In a traditional
drug development program sponsored by a large pharmaceutical company,
management decision cycles and the scarcity of internal expertise
and resources are the rate liming steps to rapid drug development.
Even when outside clinical research organizations are employed
for drug development, time savings have not been widely demonstrated
because management decision cycles are still imposed upon the
development team and autonomy is rarely allowed.
In contrast, VDDI Pharmaceuticals has created a new, virtual model
for drug development which does not suffer from these limitations
and leverages outside expertise in a much more efficient manner.
At the heart of VDDI Pharmaceuticals' business model is the interconnection
of researchers and consultants comprising each product development
team who are spread across a number of continents and time zones.
This global approach to pharmaceutical product development will
dramatically reduce the time and cost of developing breakthrough
drugs benefiting millions of people. This model has only become
feasible through the dramatic advancements in telecommunications
over the past ten years. VDDI Pharmaceuticals is the first virtual drug development
company wholly based on internet technology.
VDDI Pharmaceuticals will
be run by a small core group of employees and will contract with
consultants for product development and clinical studies on a
product-by-product basis. VDDI Pharmaceuticals will leverage available technology
and resources instead of investing precious capital on "bricks
and mortar" infrastructure. VDDI Pharmaceuticals believes that product development
costs will be reduced by up to 25%, and development time will
be reduced by up to 50%. Drawing from an international network
of employees, advisors, subcontractors and strategic alliances,
VDDI Pharmaceuticals will utilize a broad range of senior-level business and scientific
expertise to research and evaluate product opportunities.
VDDI Pharmaceuticals will
license early-stage products and complete preclinical, early regulatory
registrations, and Phase I and Phase II clinical studies. The
products will then be licensed to large pharmaceutical firms for
phase III clinical studies and subsequent sharing in the royalties
from worldwide marketing and distribution.
